Alan Hoberman
Director/Board Member presso BIOXYTRAN, INC.
Patrimonio netto: 106 999 $ in data 31/03/2024
Profilo
Alan M.
Hoberman is currently the President & Chief Executive Officer at Argus International, Inc. and an Independent Director at BioXyTran, Inc. He previously worked as the Executive Director-Site Operations & Toxicology at Argus Research Laboratories, Inc. from 1991 to 2013, and as an Independent Director at Boston Therapeutics, Inc. from 2014 to 2017.
He also served as an Independent Director and Director at Oxygen Therapy, Inc. and BioXyTran, Inc., respectively.
Hoberman received his undergraduate degree from Drexel University, his graduate degree from The University of Arkansas, and his doctorate from Pacific Western University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BIOXYTRAN, INC.
0.61% | 19/04/2024 | 1 009 422 ( 0.61% ) | 106 999 $ | 31/03/2024 |
Posizioni attive di Alan Hoberman
| Società | Posizione | Inizio |
|---|---|---|
| BIOXYTRAN, INC. | Director/Board Member | 02/11/2018 |
Argus International, Inc.
 Argus International, Inc. Industrial MachineryProducer Manufacturing Argus International, Inc. designs and manufactures machinery for the processing of printed circuit boards. Its products include LPI Spray Coating, Thin Film Coating, Hot Air Leveling, and Fusing. The company was founded on March 1, 1965 and is headquartered in Ringoes, NJ. | Chief Executive Officer | - |
Precedenti posizioni note di Alan Hoberman
| Società | Posizione | Fine |
|---|---|---|
Oxygen Therapy, Inc.
 Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Director/Board Member | 03/08/2018 |
| NANOMIX CORPORATION | Director/Board Member | 15/09/2017 |
| Argus Research Laboratories, Inc. | Corporate Officer/Principal | 01/01/2013 |
BioXyTran, Inc. /Old/
 BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Director/Board Member | - |
Formazione di Alan Hoberman
| Drexel University | Undergraduate Degree |
| The University of Arkansas | Graduate Degree |
| Pacific Western University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Argus International, Inc.
Argus International, Inc. Industrial MachineryProducer Manufacturing Argus International, Inc. designs and manufactures machinery for the processing of printed circuit boards. Its products include LPI Spray Coating, Thin Film Coating, Hot Air Leveling, and Fusing. The company was founded on March 1, 1965 and is headquartered in Ringoes, NJ. | Producer Manufacturing |
| Argus Research Laboratories, Inc. | |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
| BioXyTran, Inc. |
- Borsa valori
- Insiders
- Alan Hoberman
